碳酸氢钠在CKD 3-4期患者中的随机对照试验
这项多中心随机安慰剂对照试验纳入149例CKD 3-4期患者,比较碳酸氢钠(0.4 mEq/kg理想体重/天)与安慰剂。碳酸氢钠显著升高血清碳酸氢盐并降低血钾,但肌肉功能和骨密度无显著差异。
要点
- 碳酸氢钠显著升高CKD 3-4期患者血清碳酸氢盐水平。
- 肌肉功能(坐立试验)和骨密度无显著改善。
- 血钾下降呈边缘统计学意义,需更大样本评估肾脏影响。
核心结论
- 碳酸氢钠治疗CKD 3-4期患者显著升高血清碳酸氢盐并降低血钾,但肌肉功能和骨密度无显著差异。
研究设计与样本
- 多中心、随机、安慰剂对照临床试验,纳入149例CKD 3-4期患者,随机接受碳酸氢钠(0.4 mEq/kg理想体重/天,n=74)或安慰剂(n=75)。
主要发现
- 碳酸氢钠组随访2、6、12、24个月平均血清碳酸氢盐为26.4±2.2、25.5±2.3、25.6±2.6、24.4±2.8 mEq/L,显著高于安慰剂组(P<0.001)。
- 坐立试验5次重复P=0.1,10次重复P=0.07,骨密度P=0.3,均无显著差异。
- 碳酸氢钠组血钾下降呈边缘统计学意义(P=0.05)。
- 两组估算肾小球滤过率、血压、体重、严重不良事件及肌肉基因表达水平无显著差异。
关键数值与推荐
- 基线平均血清碳酸氢盐24.0±2.2 mEq/L,基线平均eGFR 36.3±11.2 mL/min/1.73m2。
临床怎么用
- 对CKD 3-4期患者使用碳酸氢钠可升高血清碳酸氢盐并可能降低血钾,但未显示改善肌肉功能或骨密度。
局限性
- 基线平均血清碳酸氢盐处于正常范围。
- 需要更大规模试验评估对肾功能的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Metabolic acidosis associated with chronic kidney disease (CKD) may contribute to muscle dysfunction and bone disease. We aimed to test whether treatment with sodium bicarbonate improves muscle and bone outcomes. STUDY DESIGN: Multicenter, randomized, placebo-controlled, clinical trial. SETTING & PARTICIPANTS: 149 patients with CKD stages 3 and 4 between July 2011 and April 2016 at 3 centers in Cleveland, OH, and the Bronx, NY. INTERVENTION: Sodium bicarbonate (0.4 mEq per kg of ideal body weight per day) (n=74) or identical-appearing placebo (n=75). OUTCOMES: Dual primary outcomes were muscle function assessed using sit-to-stand test and bone mineral density. Muscle biopsies were performed at baseline and 2 months. Participants were seen at baseline and 2, 6, 12, and 24 months. RESULTS: Mean baseline serum bicarbonate level was 24.0±2.2 (SD) mEq/L and mean baseline estimated glomerular filtration rate was 36.3±11.2mL/min/1.73m2. Baseline characteristics did not differ between groups. Mean serum bicarbonate levels in the intervention arm during follow-up were 26.4±2.2, 25.5±2.3, 25.6±2.6, and 24.4±2.8 mEq/L (at 2, 6, 12, and 24 months). These were significantly higher than in the placebo group (P<0.001). Compared to the placebo group, participants randomly assigned to sodium bicarbonate treatment had no significant differences in sit-to-stand time (5 repetitions: P=0.1; and 10 repetitions P=0.07) or bone mineral density (P=0.3). Sodium bicarbonate treatment caused a decrease in serum potassium levels that was of borderline statistical significance (P=0.05). There were no significant differences in estimated glomerular filtration rates, blood pressure, weight, serious adverse events, or levels of muscle gene expression between the randomly assigned groups. LIMITATIONS: Initial mean serum bicarbonate level was in the normal range. CONCLUSIONS: Sodium bicarbonate therapy in patients with CKD stages 3 and 4 significantly increases serum bicarbonate and decreases potassium levels. No differences were found in muscle function or bone mineral density between the randomly assigned groups. Larger trials are required to evaluate effects on kidney function. FUNDING: National Institutes of Health grant. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01452412.
引用
- Melamed ML, Horwitz EJ, Dobre MA, et al. Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial. Am J Kidney Dis. 2019. PMID: 31699517. doi:10.1053/j.ajkd.2019.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。